- BioPharm International, Regulatory Sourcebook October 2021
- Volume 2021 eBook
- Issue 4
NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations
Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
On Jan. 4, 2021, the National Institute of Standards and Technology (NIST) published for notice and comment proposed rulemaking regarding “
About the author
Kevin E. Noonan is a partner with McDonnell Boehnen Hulbert & Berghoff LLP and co-chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.
Article Details
BioPharm International
eBook: Regulatory Sourcebook
October 2021
Pages: 26-29
Citation
When referring to this article, please cite it as K. Noonan, “NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations," BioPharm International’s Regulatory Sourcebook eBook (October 2021)
Articles in this issue
almost 4 years ago
Industry Organizations Assist Pharma During the Pandemic and Beyondalmost 4 years ago
How Artificial Intelligence Impacts the Global Regulatory Environmentalmost 4 years ago
Selecting the Right CMC Strategy for Biologicsalmost 4 years ago
The Evolving Biosimilar Approachalmost 4 years ago
Serialization and Aggregation from a Manufacturing Perspectivealmost 4 years ago
The Real Danger of Substandard and Counterfeit COVID-19 Vaccinesalmost 4 years ago
Collecting Industry’s Thoughts on FDA FARS ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.